Evidence map›Paper›PMID 41024099›Full record

ArticleEuropean journal of medical research2025

Distribution effect of SOST on alveolar bone micro-bone formation in rats induced by Eldecalcitol.

Ying Guo, Hong Wang, Nu Mi, Qianmin Chen, RongRong Wang, Hui Ni

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying Guo *Department of Stomatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Hong Wang *Department of Stomatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Nu MiDepartment of Stomatology, Shenzhen OCT Hospital, Shenzhen, 518000, China.
Qianmin ChenDepartment of Stomatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
RongRong WangDepartment of Stomatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Hui NiDepartment of Stomatology, Shenzhen Guangming District People's Hospital, Shenzhen, 518106, China. lamnihui@163.com.

Funding

Guangdong Scientific Research Foundation A2022435Shenzhen Natural Science Fund 20220810161720001
6 · The paper itself

Abstract

objectivesThis study controlled experimental and histological study based on an ovariectomized (OVX) rat model, and aimed to clarify the distribution changes of TRAP-positive osteoclasts and sclerostin-positive osteocytes in the alveolar septal area of rats after Eldecalcitol (ELD) treatment, and to explore their association with bone metabolism-related factors, thereby preliminarily elucidating the early pathological mechanism of alveolar osteoporosis.

methodsA total of 32 female Wistar rats (8 weeks) were randomly divided into three groups: sham-operated control (Sham, n = 10), ovariectomized (OVX, n = 11), and ovariectomized treated with Eldecalcitol (OVX + ELD, n = 11). Observations were Made at different timepoints, including 1 week and 2 weeks after surgery. OVX rat models were established by bilateral ovariectomy. Eldecalcitol (0.03 µg/kg/day) was administered orally for 2 weeks starting immediately after surgery. Mandibular samples were fixed, decalcified, and prepared into thin sections for histological analyses. Osteocyte distribution and characteristics were studied in detail using TRAP staining, ALP/TRAP staining, and sclerostin/TRAP/silver triple staining techniques. In addition, double staining of RANKL and TRAP was performed to further explore the expression of bone resorption-related molecules.

resultsThe experimental results showed that in the bone groove interval area, rats that underwent ovariectomy (OVX) had a small number of TRAP-positive osteoclasts in the early stage (1 week), but this number gradually increased over time. In the OVX group after 1 week of combined treatment with Eldecalcitol, the number of TRAP-positive osteoclasts was significantly reduced. In addition, the expression of sclerostin-positive osteocytes decreased over time, but this decrease was smaller in the combination treatment group.

conclusionsThis study reveals the distribution of TRAP-positive osteoclasts and sclerostin-positive osteocytes in the alveolar septal area and their correlation with bone metabolism-related factors. Eldecalcitol treatment effectively inhibits osteoclast activity, reduces bone resorption, and significantly mitigates the reduction of sclerostin expression in osteocytes induced by ovariectomy. These findings suggest that Eldecalcitol may regulate alveolar bone metabolism partially by modulating sclerostin expression, making it a promising therapeutic strategy for osteoporosis.

Indexed as

OsteogenesisVitamin DAdaptor Proteins, Signal TransducingAnimalsBone Morphogenetic ProteinsFemaleGenetic MarkersOsteoclastsOsteocytesOvariectomyRatsRats, WistarAdaptor Proteins, Signal TransducingBone Morphogenetic ProteinseldecalcitolGenetic MarkersSost protein, ratVitamin DBone metabolismBone resorptionEldecalcitolOsteoporosisRat modelSclerostin-positive osteocytesTRAP-positive osteoclasts

Identifiers

PMID41024099
PMCPMC12481801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.